tetano
Editor, Senior Moderator
Vaccines (Basel). 2020 Mar 13;8(1). pii: E126. doi: 10.3390/vaccines8010126.
Baseline Levels of Influenza-Specific B Cells and T Cell Responses Modulate Human Immune Responses to Swine Variant Influenza A/H3N2 Vaccine.
Lai L[SUP]1[/SUP], Rouphael N[SUP]1[/SUP], Xu Y[SUP]1[/SUP], Sherman AC[SUP]1[/SUP], Edupuganti S[SUP]1[/SUP], Anderson EJ[SUP]2[/SUP], Lankford-Turner P[SUP]1[/SUP], Wang D[SUP]1[/SUP], Keitel W[SUP]3[/SUP], McNeal MM[SUP]4[/SUP], Cross K[SUP]5[/SUP], Hill H[SUP]5[/SUP], Bellamy AR[SUP]5[/SUP], Mulligan MJ[SUP]6[/SUP].
Author information
Abstract
The cellular immune responses elicited by an investigational vaccine against an emergent variant of influenza (H3N2v) are not fully understood. Twenty-five subjects, enrolled in an investigational influenza A/H3N2v vaccine study, who received two doses of vaccine 21 days apart, were included in a sub-study of cellular immune responses. H3N2v-specific plasmablasts were determined by ELISpot 8 days after each vaccine dose and H3N2v specific CD4+ T cells were quantified by intracellular cytokine and CD154 (CD40 ligand) staining before vaccination, 8 and 21 days after each vaccine dose. Results: 95% (19/20) and 96% (24/25) subjects had pre-existing H3N2v specific memory B, and T cell responses, respectively. Plasmablast responses at Day 8 after the first vaccine administration were detected against contemporary H3N2 strains and correlated with hemagglutination inhibition HAI (IgG: p = 0.018; IgA: p < 0.001) and Neut (IgG: p = 0.038; IgA: p = 0.021) titers and with memory B cell frequency at baseline (IgA: r = 0.76, p < 0.001; IgG: r = 0.74, p = 0.0001). The CD4+ T cells at Days 8 and 21 expanded after prime vaccination and this expansion correlated strongly with early post-vaccination HAI and Neut titers (p ≤ 0.002). In an adult population, the rapid serological response observed after initial H3N2v vaccination correlates with post-vaccination plasmablasts and CD4+ T cell responses.
KEYWORDS:
H3N2v; T cell responses; antibody secreting cells; influenza; vaccine
PMID:32183105DOI:10.3390/vaccines8010126
Free full text
Baseline Levels of Influenza-Specific B Cells and T Cell Responses Modulate Human Immune Responses to Swine Variant Influenza A/H3N2 Vaccine.
Lai L[SUP]1[/SUP], Rouphael N[SUP]1[/SUP], Xu Y[SUP]1[/SUP], Sherman AC[SUP]1[/SUP], Edupuganti S[SUP]1[/SUP], Anderson EJ[SUP]2[/SUP], Lankford-Turner P[SUP]1[/SUP], Wang D[SUP]1[/SUP], Keitel W[SUP]3[/SUP], McNeal MM[SUP]4[/SUP], Cross K[SUP]5[/SUP], Hill H[SUP]5[/SUP], Bellamy AR[SUP]5[/SUP], Mulligan MJ[SUP]6[/SUP].
Author information
Abstract
The cellular immune responses elicited by an investigational vaccine against an emergent variant of influenza (H3N2v) are not fully understood. Twenty-five subjects, enrolled in an investigational influenza A/H3N2v vaccine study, who received two doses of vaccine 21 days apart, were included in a sub-study of cellular immune responses. H3N2v-specific plasmablasts were determined by ELISpot 8 days after each vaccine dose and H3N2v specific CD4+ T cells were quantified by intracellular cytokine and CD154 (CD40 ligand) staining before vaccination, 8 and 21 days after each vaccine dose. Results: 95% (19/20) and 96% (24/25) subjects had pre-existing H3N2v specific memory B, and T cell responses, respectively. Plasmablast responses at Day 8 after the first vaccine administration were detected against contemporary H3N2 strains and correlated with hemagglutination inhibition HAI (IgG: p = 0.018; IgA: p < 0.001) and Neut (IgG: p = 0.038; IgA: p = 0.021) titers and with memory B cell frequency at baseline (IgA: r = 0.76, p < 0.001; IgG: r = 0.74, p = 0.0001). The CD4+ T cells at Days 8 and 21 expanded after prime vaccination and this expansion correlated strongly with early post-vaccination HAI and Neut titers (p ≤ 0.002). In an adult population, the rapid serological response observed after initial H3N2v vaccination correlates with post-vaccination plasmablasts and CD4+ T cell responses.
KEYWORDS:
H3N2v; T cell responses; antibody secreting cells; influenza; vaccine
PMID:32183105DOI:10.3390/vaccines8010126
Free full text